1. Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis
- Author
-
Benz, Fabian, Bogen, Andreas, Praktiknjo, Michael, Jansen, Christian, Meyer, Carsten, Wree, Alexander, Demir, Muenevver, Loosen, Sven, Vucur, Mihael, Schierwagen, Robert, Tacke, Frank, Trebicka, Jonel, and Roderburg, Christoph
- Subjects
Liver Cirrhosis ,stomatognathic system ,Portal Vein ,Hypertension, Portal ,Disease Progression ,Integrin-Binding Sialoprotein ,Portal Pressure ,Severity of Illness Index ,Biomarkers ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit ,3. Good health ,Retrospective Studies - Abstract
Liver cirrhosis represents the common end-stage of chronic liver diseases regardless of its etiology. Patients with compensated disease are mostly asymptomatic, however, progression to a decompensated disease stage is common. The available stratification strategies are often unsuitable to identify patients with a higher risk for disease progression and a limited prognosis. SIBLINGs, soluble glycophosphoproteins, are secreted into the blood by immune-cells. While osteopontin, the most prominent member of the SIBLINGs family, has been repeatedly associated with liver cirrhosis, data on the diagnostic and/or prognostic value of bone sialoprotein (BSP) are scarce and partly inconclusive. In this study, we analyzed the diagnostic and prognostic potential of circulating BSP in comparison to other standard laboratory markers in a large cohort of patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt (TIPS). Serum levels of BSP were similar in patients with different disease stages and were not indicative for prognosis. Interestingly, BSP serum levels did correlate inversely with portal pressure, as well as its surrogates such as platelet count, the portal vein cross-sectional area and correlated positively with the portal venous velocity. In summary, our data highlight that BSP might represent a previously unrecognized marker for portal hypertension in patients with liver cirrhosis.